CoChat

An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis

Miller, Mathew, Alvizo, Oscar, Chng, Chinping, Jenne, Stephan, Mayo, Melissa, Mukherjee, Arpan, Sundseth, Stuart, Chintala, Avinash, Penfield, Jonathan, Riggins, James, Zhang, Xiyun, Sero, Antoinette, Dassie, Justin, Leatherbury, Neil, Baskerville, Scott, Huisman, Gjalt · 2022

Preprint — published as 10.1039/d4fd00023d

PreprintCited by 11

The DOI matches its Crossref record.

Abstract

Messenger RNA (mRNA) therapies have recently gained tremendous traction with the approval of mRNA vaccines for the prevention of SARS-CoV-2 infection. However, manufacturing challenges have complicated large scale mRNA production, which is necessary for the clinical viability of these therapies. Not only can the incorporation of the required 5’ 7-methylguanosine cap analog be inefficient and costly, in vitro transcription (IVT) using wild-type T7 RNA polymerase generates undesirable double-stranded RNA (dsRNA) byproducts that elicit adverse host immune responses and are difficult to remove at large scale. To overcome these challenges, we have engineered a novel RNA polymerase, T7-68, that co-transcriptionally incorporates both di- and tri-nucleotide cap analogs with high efficiency, even at reduced cap analog concentrations. We also demonstrate that IVT products generated with T7-68 have reduced dsRNA content.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.09.01.506264

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 44

  1. A.-M. H. Jiao Wei, 2022, The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines, Cancer Treatment Reviews, 107, 102405, 10.1016/j.ctrv.2022.102405 · DOI · Paper page
  2. H. M. C. H. Y. H. B. F. A. K. H. A. S. C. P. A. H. A. K. Z. A. K. E. J. A. K. A. L. A. S. R. A. R. H. N. G. A. K. M. A. R. H. B. A. A.-T. Tang P, 2021, BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar, Nature Medicine, 27, 2136, 10.1038/s41591-021-01583-4 · DOI · Paper page
  3. 10.1093/nar/gkw551 · DOI · Paper page
  4. 2020, The promise of mRNA vaccines: a biotech and industrial, npj Vaccines, 5, 11, 10.1038/s41541-020-0159-8 · DOI · Paper page
  5. 10.1016/j.omtn.2018.06.010 · DOI · Paper page
  6. 10.1261/rna.056614.116 · DOI · Paper page
  7. J. Tate , R. Boldt , B. McFadden , S. D’Costa , N. Lewandowski , A. Shatzer , P. Gollnick and R. Condit , “Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutant,” Virology, no. 487, pp. 27–40, 2016. · doi:10.1016/j.virol.2015.10.011
  8. 10.1073/pnas.91.15.6972 · DOI · Paper page
  9. 10.1093/nar/gkq347 · DOI · Paper page
  10. 10.1038/nrd4278 · DOI · Paper page
  11. 2021, Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety, Biomedicines, 9, 530, 10.3390/biomedicines9050530 · DOI · Paper page
  12. K.. Karikó , H.. Muramatsu , J.. Ludwig and D.. Weissman , “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA,” Nucleic Acids Research, vol. 39, no. 21, p. p, 2011. · DOI · Paper page
  13. 10.1016/j.coi.2020.01.008 · DOI · Paper page
  14. M.. Baiersdörfer , G.. Boros , H.. Muramatsu , A. J. Mahiny , I.. Vlatkovic , U.. Sahin and K.. Karikó , “A facile method for removal of dsRNA contaminant from in vitro-transcribed mRNA,” Molecular therapy. Nucleic acids, vol., no., p., 2019. · DOI · Paper page
  15. 10.1261/rna.073858.119 · DOI · Paper page
  16. 10.1017/S1355838201014078 · doi:10.1017/s1355838201014078
  17. 10.1261/rna.7380904 · DOI · Paper page
  18. J. M. A. E. S. C. Henderson, 2021, Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription, CURRENT PROTOCOLS, 1, e39, 10.1002/cpz1.39 · DOI · Paper page
  19. 2020, RIG-I-like receptors: their regulation and roles in RNA sensing, Nature Reviews Immunology, 20, 537, 10.1038/s41577-020-0288-3 · DOI · Paper page
  20. 2021, Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines, ACS central science, 7, 748, 10.1021/acscentsci.1c00197 · DOI · Paper page
  21. 10.1021/bi000579d · DOI
  22. 10.1093/nar/gky177 · DOI · Paper page
  23. 10.1074/jbc.270.11.6298 · DOI · Paper page
  24. 10.1093/nar/gky796 · DOI · Paper page
  25. 10.1146/annurev-immunol-042718-041356 · DOI · Paper page
  26. 10.1093/nar/19.11.2993 · DOI · Paper page
  27. 2019, RIG-I Recognition of RNA Targets: The Influence of Terminal Base Pair Sequence and Overhangs on Affinity and Signaling, Cell Reports, 29, 3807, 10.1016/j.celrep.2019.11.052 · DOI
  28. 10.1126/science.1155406 · DOI · Paper page
  29. 2014, sRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects, Journal of interferon & cytokine research, 34, 427, 10.1089/jir.2014.0034 · DOI
  30. 10.1093/nar/gkq347 · DOI · Paper page
  31. S. S. S. W. A. G. C. B. A. J. K. Y. Kim SC, 2022, Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency, Mol Cell Toxicol, 18, 1, 10.1007/s13273-021-00171-4 · DOI · Paper page
  32. J. K. E. N. D. K. R. T. R. K. P. J. S. J. D. G. M. N. a. J. J. Marcin Warminski, 2021, Structural Insights into the Interaction of Clinically Relevant Phosphorothioate mRNA Cap Analogs with Translation Initiation Factor 4E Reveal Stabilization via Electrostatic Thio-Effect, ACS Chemical Biology, 16, 334, 10.1021/acschembio.0c00864 · DOI
  33. I. K. M. A. E. Kocmik, 2018, Modified ARCA analogs providing enhanced translational properties of capped mRNAs, CELL CYCLE, 17, 1624, 10.1080/15384101.2018.1486164 · DOI · Paper page
  34. J. A. R. H. Kern, 1999, Application of a Fed-Batch System To Produce RNA by In Vitro Transcription, BIOTECHNOLOGY PROGRESS, 15, 174, 10.1021/bp990008g · doi:10.1021/bp990008g
  35. 2021, Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype, VIRUSES, 13, 270, 10.3390/v13020270 · DOI · Paper page
  36. D. Weismann , N. Pardi , H. Muramatsu and K. Kariko , “HPLC Purification of In Vitro Transcribed Long RNA,” in Synthetic Messenger RNA and Cell Metabolism Modulation, Totowa, N.J., Humana Press, 2013, pp. 43–54. · DOI · Paper page
  37. L. J. P. G. B. K. M.-M. A. G. P. W. Y. V. D. E. S. S. D. Jelinek I, “TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.,” J Immunol, vol. 186, no. 4, pp. 2422–9, J Immunol. · DOI · Paper page
  38. A. V. a. S. K. A. Dallas, “Principles of Nucleic Acid Cleavage by Metal Ions,” in Nucleic Acids and Molecular Biology, Artificial Nucleases, Berlin, Springer-Verlag, 2004, pp. 61–71. · DOI
  39. S. Tinar , “The EMA covid-19 data leak, and what it tells us about mRNA instability,” BMJ, vol. 372, p. n627, 2021. · DOI
  40. 10.1016/j.ymthe.2017.02.005 · DOI · Paper page
  41. 10.1093/nar/gkr586 · DOI · Paper page
  42. 10.1038/mt.2008.200 · DOI · Paper page
  43. “How biomanufacturing can save the world,”, 2021, Nature Biotechnology, 39, 1315, 10.1038/s41587-021-01132-x · doi:10.1038/s41587-021-01132-x
  44. 10.1126/sciadv.aaz6893 · DOI · Paper page

Cited by

See all 11

Metadata

Authors
Miller, M., Alvizo, O., Chng, C., Jenne, S., Mayo, M., Mukherjee, A., Sundseth, S., Chintala, A., Penfield, J., Riggins, J., Zhang, X., Sero, A., Dassie, J., Leatherbury, N., Baskerville, S., & Huisman, G.
Publisher
openRxiv
Published
2022-09-02
Cited by
11
References
0
Type
Preprint

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. https://app.cochat.ai/papers/10.1101/2022.09.01.506264
The paper
Miller, M., Alvizo, O., Chng, C., Jenne, S., Mayo, M., Mukherjee, A., Sundseth, S., Chintala, A., Penfield, J., Riggins, J., Zhang, X., Sero, A., Dassie, J., Leatherbury, N., Baskerville, S., & Huisman, G. (2022). An Engineered T7 RNA Polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. https://doi.org/10.1101/2022.09.01.506264

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.